Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994578 | 0.83 | HPGDS (0.36) | HPGDSKCNH2L3MBTL1HDAC1HDAC8 | |
| SCHEMBL23995230 | 0.76 | CHRNB2 (0.39) | SLC6A4CHRNB2CHRNA4SLC6A2SLC6A3 | |
| SCHEMBL23995555 | 0.76 | HTR2C (0.43) | SLC6A4CHRNB2CHRNA4SLC6A2SLC6A3 | |
| SCHEMBL23994585 | 0.75 | IDO1 (0.35) | CHRNB2CHRNA4HTR2CHTR2BHTR2A | |
| SCHEMBL6468609 | 0.74 | MTNR1A (0.37) | HPGDSKCNH2L3MBTL1HDAC1HDAC8 | |
| SCHEMBL16705084 | 0.74 | CYP1A2 (0.46) | HPGDSKCNH2L3MBTL1HDAC1HDAC8 | |
| SCHEMBL25005433 | 0.73 | ALDH1A1 (0.46) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL25004989 | 0.73 | HTR2C (0.40) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL25004716 | 0.72 | SLC6A4 (0.39) | SLC6A4CHRNB2CHRNA4SLC6A2SLC6A3 | |
| SCHEMBL6370641 | 0.72 | HPGDS (0.37) | HPGDSKCNH2L3MBTL1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | SLC6A4 1120/4885HPGDS 915/4885CHRNB2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.